Skip to main content
Log in

Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

A randomized study involving pregnant women was conducted to compare the effectiveness of a single intravenous (IV) injection of carbetocin with that of a standard 2-h oxytocin IV infusion with respect to intraoperative blood loss in the prevention of uterine atony after cesarean section (CS). The two treatments also were compared for safety and ability to maintain adequate uterine tone and to reduce the incidence and severity of postpartum hemorrhage (PPH) in women at risk for this condition.

Methods

Between 1 September 2007 and 5 January 2008, we enrolled 104 patients with at least one risk factor for PPH undergoing CS in a randomized, controlled clinical trial. We compared the effect of a single 100 microg IV dose of carbetocin with that of a standard 2-h ten international units (IU) IV infusion of oxytocin. The primary outcome was the proportion of patients requiring additional oxytocic intervention for uterine atony. Fiftytwo women received 100 microg carbetocin IV immediately after placental delivery, while 52 women received 10 IU oxytocin IV infusion. Complete blood count was collected at entry and 24 h postpartum. All outcome measures, including the need for additional uterotonic agents or uterine massage, and blood loss, were analyzed using chi-square, Fisher exact, and Student’s t tests.

Results

A single 100 microg IV injection of carbetocin was as effective as a continuous 2-h infusion of oxytocin in controlling intraoperative blood loss after placental delivery. Mean blood loss after carbetocin administration was 30 ml less than after oxytocin administration (P = 0.5). The percentage of patients with blood loss ≤500 ml was greater with carbetocin (81 vs. 55%; P = 0.05). Carbetocin enhanced early postpartum uterine involution. The fundus was below the umbilicus in more patients who received carbetocin at 0, 2, 6, and 24 h on the ward (P < 0.05). The main additional uterotonic agent used was a further administration of oxytocin (20 IU in physiological solution 500 ml at an infusion rate of 200 ml/h). In the carbetocin group, 20 of the 52 women (38.4%) required at least one uterine massage compared to 30 of the 52 women (57.7%) in the oxytocin group (P < 0.01). Overall, uterotonic intervention was clinically indicated in two of the women (3.8%) receiving carbetocin compared to five of the women (9.6%) given an IV oxytocin infusion (P < 0.01). The odds ratio of treatment failure requiring oxytocic intervention was 1.83 (95% confidence interval, CI, 0.9–2.6) times higher in the oxytocin group compared with the carbetocin group.

Conclusions

Carbetocin makes possible to obtain, with a single IV injection, results equivalent to those of oxytocin on the maintenance of uterine tonicity and the limitation of blood losses, in the peri- and in the post-operative period, during a delivery by CS. It has in addition a comparable tolerance. Even in our series adverse events are practically of the same type and similar frequency in both study groups. Thus, the effectiveness of carbetocin consists, thanks to its long half-life, on an unique injection, whereas oxytocin requires repeated injections or a perfusion of several hours, with a variability of the administered doses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McDonald S (2007) Management of the third stage of labor. J Midwifery Womens Health 52:254–261. doi:10.1016/j.jmwh.2007.02.012

    Article  PubMed  Google Scholar 

  2. Chong YS, Su LL, Arulkumaran S (2004) Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. Curr Opin Obstet Gynecol 16:143–150. doi:10.1097/00001703-200404000-00008

    Article  PubMed  Google Scholar 

  3. Mousa HA, Cording V, Alfirevic Z (2008) Risk factors and interventions associated with major primary postpartum hemorrhage unresponsive to first-line conventional therapy. Acta Obstet Gynecol Scand 87:652–661. doi:10.1080/00016340802087660

    Article  PubMed  Google Scholar 

  4. Wandabwa J, Doyle P, Todd J et al (2008) Risk factors for severe post partum haemorrhage in Mulago hospital, Kampala, Uganda. East Afr Med J 85:64–71

    PubMed  CAS  Google Scholar 

  5. Hunter DJ, Schulz P, Wassenaar W (1992) Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther 52:60–67

    PubMed  CAS  Google Scholar 

  6. Su LL, Chong YS, Samuel M (2007) Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev 3:CD005457

    Google Scholar 

  7. Prendiville WJ, Harding JE, Elbourne DR et al (1988) The Bristol third stage trial: active versus physiological management of third stage of labour. BMJ 297:1295–1300

    Article  PubMed  CAS  Google Scholar 

  8. Eulenberger K (2000) Medical treatment of dystocia in zoo animals. Dtsch Tierarztl Wochenschr 107:512–515

    PubMed  CAS  Google Scholar 

  9. Handler J, Hoffmann D, Weber F et al (2006) Oxytocin does not contribute to the effects of cervical dilation on progesterone secretion and embryonic development in mares. Theriogenology 66:1397–1404. doi:10.1016/j.theriogenology.2006.04.032

    Article  PubMed  CAS  Google Scholar 

  10. Cort N, Einarsson S, Aström G (1982) Effect of oxytocin and its long-acting analog on milk let-down and intramammary pressure in healthy lactating sows. Am J Vet Res 43:1283–1285

    PubMed  CAS  Google Scholar 

  11. Atke A, Vilhardt H (1987) Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin. Acta Endocrinol (Copenh) 115:155–160

    CAS  Google Scholar 

  12. Dansereau J, Joshi AK, Helewa ME et al (1999) Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 180:670–676. doi:10.1016/S0002-9378(99)70271-1

    Article  PubMed  CAS  Google Scholar 

  13. Norström A, Andersson A, Vilhardt H (1990) Contractile effect of oxytocin and 1-deamino-1-carba-2-tyrosine (O-methyl)-oxytocin in myometrial tissue from non-pregnant and term pregnant women. Acta Endocrinol (Copenh) 122:566–568

    Google Scholar 

  14. Engstrøm T, Barth T, Melin P et al (1998) Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 355:203–210. doi:10.1016/S0014-2999(98)00513-5

    Article  PubMed  Google Scholar 

  15. Boucher M, Horbay GL, Griffin P et al (1998) Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol 18:202–207

    PubMed  CAS  Google Scholar 

  16. Bajcsy AC, Szenci O, van der Weijden GC et al (2006) The effect of a single oxytocin or carbetocin treatment on uterine contractility in early postpartum dairy cows. Theriogenology 65:400–414. doi:10.1016/j.theriogenology.2005.05.040

    Article  PubMed  CAS  Google Scholar 

  17. Silcox J, Schulz P, Horbay GL et al (1993) Transfer of carbetocin into human breast milk. Obstet Gynecol 82:456–459

    PubMed  CAS  Google Scholar 

  18. Leung SW, Ng PS, Wong WY et al (2006) A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour. BJOG 113:1459–1464. doi:10.1111/j.1471-0528.2006.01105.x

    Article  PubMed  CAS  Google Scholar 

  19. Bose P, Regan F, Paterson-Brown S (2006) Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG 113:919–924. doi:10.1111/j.1471-0528.2006.01018.x

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

Authors do not have a financial relationship with the organization that sponsored the research. They also state that they have had full control of all primary data and that they agree to allow the Journal to review their data if requested.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ciro Comparetto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borruto, F., Treisser, A. & Comparetto, C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet 280, 707–712 (2009). https://doi.org/10.1007/s00404-009-0973-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-009-0973-8

Keywords

Navigation